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PPP to 69,231 US-$ PPP. A co-morbid conduct disorder was reported to be the most 
influential factor for increased health care costs. All CEA analysed psychotherapy 
interventions. While CEA reporting cost per avoided parasuicide event indicated 
favourable incremental cost effectiveness ratios, CEA reporting cost per quality-
adjusted life years (QALY) indicated just weak cost-effectiveness. ConClusions: 
BPD is associated with high costs. Available COI provide a first insight into the 
structure of cost and its predictors. There are no CEA regarding medication for 
BPD. Evidence regarding the cost-effectiveness of psychotherapy interventions is 
ambiguous. Future research should promote the understanding of the economic 
aspects of BPD and determine the societal value of its treatment. In this context 
high methodical standards are particularly important.
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objeCtives: To calculate the annual health insurance treatment cost of epilepsy 
disease in Hungary. Methods: The data derive from the financial database of the 
Hungarian National Health Insurance Fund Administration (NHIFA), the only health 
care financing agency in Hungary. We analyzed the health insurance treatment 
cost and the number of patients for the year 2010. The following cost categories 
were included into the study: out-patient care, in-patient care, CT-MRI, PET, home 
care, transportation, general practitioner, drugs and medical devices. Results: 
The Hungarian National Health Insurance Fund Administration spent 6.341 billion 
Hungarian Forint (HUF) (23.026 million EUR) for the treatment of epilepsy patients. 
The annual average expenditure per patient was 41900 HUF (152.1 EUR) while the 
average expenditure per one inhabitant was 633 HUF (2.3 EUR). Major cost drivers 
were pharmaceuticals (6.3 % of total health insurance costs), general practitioners 
(13.1 %) and acute inpatient care (11.4 %). The number of patients with epilepsy was 
151 per 100000 populations. We found the highest patient number in pharmaceuti-
cal budget (151357 patients), out-patient care (131280 patients) and general practi-
tioners (86704 patients). ConClusions: Epilepsy disease represents a significant 
burden for the health insurance system. Pharmaceutical treatment is the major 
cost driver for epilepsy disease in Hungary.
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objeCtives: To compare health care resource utilization (HRU) and costs among 
children/adolescents with attention deficit/hyperactivity disorder (ADHD) in Quebec, 
Canada, who received an atypical antipsychotic (AAP) as either augmentation or 
alternative therapy to stimulant, before vs. after initiating the AAP. Methods: 
Patients (6–17 years) with ≥ 2 documented ADHD diagnoses (ICD-9 codes: 314.0–
314.9), who used stimulants for ≥ 30 days and either switched to an AAP or aug-
mented stimulants with an AAP, were identified in Quebec’s health care database, 
the Régie de l’assurance maladie du Québec between 03/2007 and 02/2012. Patients 
with a documented diagnosis for which AAPs are indicated were excluded. All-
cause and ADHD-related HRU and costs (from a public payer’s perspective in 2012 
Canadian dollars) were compared between the 6-month period before (pre-index) 
and after (post-index) patients’ first AAP prescription claim. Results: A total of 453 
children/adolescents met the inclusion criteria (54.5% switched from stimulants to 
AAPs and 45.5% augmented stimulants with AAPs). The mean age was 10.4 years 
(SD= 2.5) and 25.4% were female. The most prevalent documented mental comorbidi-
ties in the pre-index period were adjustment reaction (7.1%), anxiety disorder (5.1%), 
and learning disability (4.4%). Risperidone (81.7%) and quetiapine (16.3%) were the 
most common AAPs initiated. Compared to the pre-index period, patients incurred, 
on average, more all-cause outpatient visits and costs (3.2 vs. 4.6; $207 vs. $303), 
prescription fills and costs (13.3 vs. 22.2; $710 vs. $889), total medical costs ($644 vs. 
$1,096), and total health care costs ($1,354 vs. $1,985) (all p< 0.05) during the post-
index period. Similarly, ADHD-related total health care costs ($835 vs. $1,269; p< 0.05) 
were higher during the post-index period; all-cause and ADHD-related total health 
care costs increased by 46.6% and 52.0%, respectively. ConClusions: Children/
adolescents with ADHD, who received an AAP as either augmentation or alternative 
therapy to stimulant, incurred higher HRU and costs after AAP initiation, mostly 
through ADHD-related HRU.
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objeCtives: The goal of our research was to assess and calculate the costs of 
antipsychotic treatment of schizophrenia patients in Hungary, using the database 
of the National Health Insurance Fund (NHIF). Based on the results of a recently 
published study using real world data (Bitter et al. 2013.) we focused especially on 
the costs linked to the early medication discontinuation and poor adherence of 
schizophrenia patients. Methods: In Hungary all medicines which are purchased 
with reimbursement are documented in the centralized register of the NHIF since 
1998. We analyzed the Payer’s database taking into account the time to treatment 
discontinuation results of the Bitter et al. study. We calculated the yearly aver-
age costs of schizophrenia treatment both per patient, and both per substance 
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objeCtives: To gather data concerning burden of schizophrenia in seven Central 
and Eastern European (CEE) countries (Croatia, Estonia, Hungary, Poland, Serbia, 
Slovakia, Slovenia) taking into account: epidemiology, clinical guidelines and rec-
ommendations, current standards of care, costs of illness, resource utilisation, 
health-related quality of life (HRQoL), stigmatisation and discrimination related 
to schizophrenia. The project focused on negative symptoms (NS). Methods: A 
targeted search was performed focused on publications issued from 1995 onwards 
and indexed in the following databases: PubMed, Cochrane Library, and Centre for 
Review and Dissemination. Moreover, searches for literature in local languages 
from each country of interest were conducted. Results: Fourteen reviews related 
to schizophrenia epidemiology were identified and revealed that the mean inci-
dence of schizophrenia varied greatly from 0.04 to 0.58 per 1,000 population and 
lifetime prevalence from 0.4% to 1.4%. At least one negative symptom was found 
to be present in 57.6% of schizophrenia patients and in 50–90% of individuals expe-
riencing their first schizophrenia episode. Primary NS were observed in 10–30% 
of patients. Mortality of schizophrenia patients was greater than in the general 
population (Standardised Mortality Ratio varies between 2.58 and 4.3), potentially 
due to increased suicide risk, effect of illness on lifestyle and environment, and 
side effects of disease treatment. Identified guidelines indicate a role for second-
generation antipsychotics in NS treatment, nevertheless the development of novel 
therapeutic approaches should be pursued actively. Thirty-seven primary publica-
tions identified from the seven CEE countries which relate to HRQoL of patients 
and caregivers revealed that the disease greatly affects HRQoL of hospitalised 
patients and has a significant negative impact on caregivers’ QoL. ConClusions: 
The literature review confirmed that schizophrenia is one of the most common 
and burdensome mental illnesses, with NS present in a relatively large percent-
age of patients.
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objeCtives: To assess the excess direct medical costs associated with a diagnosis of 
attention-deficit/hyperactivity disorder (ADHD) in Germany. Methods: Nordbaden 
is a region in Southwestern Germany with a population of 2.74 million. Regional 
sociodemographics and health care provider density are well understood and reflect, 
with few exceptions, respective national averages. The Nordbaden database cov-
ers the total regional population insured by SHI (2.24 million lives), integrating 
administrative data from the organization of physicians registered with statutory 
health insurance (SHI) and SHI, allowing patient-centered evaluation of health care 
utilization and direct medical cost for years 2003 to 2009. Patients with a diagnosis 
of ADHD were compared to a control group matched by age, gender, and type of 
health insurance within SHI. Here we report on years 2006-2009, as nonpharmaco-
logical therapy-related cost data were not fully available for earlier years. Results: 
Average annual total cost per ADHD patient increased from € 897 in 2006 to € 1,006 in 
2009 (controls, € 261 in 2006 and € 337 in 2009). Cost per patient correlated positively 
with age, and female patients were generally more costly than males (total as well as 
excess costs). Increasing severity and comorbidity were also associated with higher 
costs per patient. Physician services constituted the major cost component (on 
average, overall, € 653 per case in 2009), followed by pharmacological therapy (€ 330 
in 2009). ConClusions: The average excess cost (from the perspective of German 
SHI) per ADHD patient (over all age groups and irrespective of gender, compared 
to matched controls) was € 669 per year in 2009. Extrapolation from the regional to 
the national level suggests annual outpatient treatment costs attributable to ADHD 
in the magnitude of € 500 million (2009), from the payer’s perspective of SHI. This 
estimate compares to total annual expenditures for health services by German SHI 
of € 160 billion in 2009.
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objeCtives: The borderline personality disorder (BPD) is a common mental dis-
order. It is frequently associated with various mental co-morbidities and causes a 
fundamental loss of functioning. Furthermore, economically relevant consequences 
such as high utilization of inpatient and emergency room treatment or reduced 
productivity at work have been reported. The aim of this study is to present the 
existing health economic evidence regarding BPD and to point out implications 
for further research. Methods: We performed a systematic literature search in 
MEDLINE, EMBASE, PsycInfo and NHSEED to identify cost-of-illness studies (COI), 
cost-effectiveness analyses (CEA) and other cost studies (OCS) regarding BPD. Cost 
data were inflated to the year 2010 and converted into US-$ using purchasing power 
parities (PPP). Quality assessment of the studies was performed by means of a 
standardised quality checklist. Results: We identified three COI, eight CEA and 
six OCS. The methodical quality was moderate. Depending on study perspective 
and considered cost categories cost per patient and year ranged from 18,306 US-$ 
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treatment option as compared with escitalopram,sertraline, and venlafaxine in 
a matrix comparator, with regard to side effects especially sexual dysfunction, 
agomelatine should be considered as the most cost-effective option for treat-
ment of depression.
PMH34
cost-effectIveness of PalIPerIdone PalMItate for tHe treatMent of 
scHIzoPHrenIa In gerMany
Zeidler J.1, Mahlich J.C.2, Greiner W.3, Heres S.4
1Leibniz University Hannover, Hannover, Germany, 2Janssen-Pharmaceutical companies of 
Johnson & Johnson, Neuss, Germany, 3School of Public Health, Bielefeld University, Bielefeld, 
Germany, 4Technical University of Munich, Munich, Germany
objeCtives: Treatment with antipsychotic medication is an important element of 
relapse prevention in the management of schizophrenia and can reduce inpatient 
stays. Recently, the long-acting atypical antipsychotic paliperidone long-acting 
injectable (PLAI), a once-monthly LAI antipsychotic, was approved for treatment 
of schizophrenia in Germany. The study aims at estimating, based on a previously 
published model, the cost-effectiveness of paliperidone long-acting injections com-
pared to other common antipsychotic treatment strategies in patients diagnosed 
with schizophrenia in Germany. Methods: A Markov decision analytic model was 
adapted to the German health care system. The model considers the cost-effective-
ness for PLAI as a maintenance treatment for patients with schizophrenia from the 
payer perspective. The patients transition between eight health states on a monthly 
basis over a 5-year time horizon. As therapeutic strategies PLAI, quetiapine, risperi-
done long-acting injections (RLAI), oral olanzapine, oral risperidone, zuclopenthixol 
decanoate, olanzapine long-acting injections (OLAI), oral typical and oral atypical 
were compared. Probability of relapse, level of adherence, side effects and treatment 
discontinuation were derived from the Swedish original model. Input factors regard-
ing resource use and costs were estimated and adjusted for the German health care 
system. A probabilistic sensitivity analyses using cost-effectiveness scatter plots 
was performed to visualize the robustness of the results. Results: In base case 
scenario PLAI is superior to RLAI in gained quality adjusted life years (QALYs) and 
avoided relapses. Relative to all other treatment strategies PLAI is more effective 
with regard to gained QALYs and avoided relapses but results in higher treatment 
costs over a 5-year horizon in base case scenario. The results were tested in proba-
bilistic sensitivity analyses ConClusions: PLAI dominates RLAI and compared to 
the other treatment strategies PLAI has shown to be more effective but results in 
higher costs in base case scenario.
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Depression is present in 10% of patients attending primary care services and is 
generally not identified. In Mexico it is estimated a prevalence of 12% to 20% among 
adults between 18-65 years old. Up to 75% of patients treated with a selective inhibi-
tor of serotonin reuptake (SSRIs) are not responding adequately. Atypical antipsy-
chotics are an effective alternative for these patients. objeCtives: To evaluate the 
cost-effectiveness (CE) of extended release (XR) quetiapine as adjunctive therapy 
(AT) in patients with major depressive disorder (MDD) that doesn’t respond to 
antidepressant treatment (AD), compared with other antipsychotics listed in the 
Mexican Formulary (aripiprazole and olanzapine). Methods: A Markov model 
was developed to perform and incremental analysis with weekly cycles during 
eight weeks time horizon, based on the meta-analysis developed by Komossa et.al 
in 2010. Health states: remission, relapse and discontinuation of treatment. The 
model estimates the remission time gained (RG) by each AT alternative. The analy-
sis was done from society perspective, considered direct costs, and reported in 
2013 US dollars. Results: Patients with AT with quetiapine XR had 1.83 weeks 
of RG, while patients under aripiprazole and olanzapine obtained 1.5 and 1.72 
weeks of RG, respectively. Quetiapine XR compared to olanzapine generated an 
additional cost per patient of $94.70, with additional RG of 0.11 weeks and ICER 
of $881.73. Quetiapine XR dominated extendedly to aripiprazole. Robustness of 
results were confirmed by additional deterministic and probabilistic sensitivity 
analysis. ConClusions: The use of quetiapine XR as adjuvant treatment for non-
responders patients is a cost-effective compared to aripiprazole and olanzapine, 
and could be considered as an option in an institutional setting.
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objeCtives: Sexual dysfunctions (SD) is a common adverse event of antidepressants. 
It has a lasting impact on quality of life and is associated with an increased risk of 
early treatment discontinuation. Using an open-source Discrete Event Simulation 
model (https://open-model-mdd.org/), we performed a cost-effectiveness analysis 
comparing alternative sequences of treatments, to determine whether an antidepres-
sant with moderate efficacy and reduced risk of SD should be positioned before or 
after a treatment with high efficacy and average risk of SD. Methods: The model 
used was designed to simulate costs and QALYs in cohorts of patients with major 
depressive disorder (MDD), under alternative treatment strategies over 5 years. 
Each strategy consisted of up to 4 lines of treatment, with possibility to switch to 
different drugs when a patient experienced adverse events or lack of efficacy. We 
between 2006 and 2012. Results: Our findings indicate that in the assessed time 
period an average yearly amount of approximately € 5,5 million (calculation based 
on yearly average EUR/HUF exchange rates) is spent on second generation antip-
sychotics, which are prescribed and purchased with reimbursement but finally 
not used by the patients due to early medication discontinuation. Based on our 
calculations, the average yearly treatment costs of antipsychotics increased from 
€ 612 (2006) to € 974 (2012) per patient in the assessed time period. The analysis of 
the NHIF database resulted, that the average yearly expenditure on different antip-
sychotics, varied between € 173 and € 2420 per patient. ConClusions: All-cause 
medication discontinuation is a major concern in the treatment of schizophrenia 
both from a clinical and both from a health economic perspective. In order to 
ensure resources are spent cost-effectively, it is crucial to identify methods which 
can improve treatment continuation and adherence of schizophrenia patients 
in the future.
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objeCtives: To compare the effect of adjunctive therapy with pregabalin versus 
usual care (UC) on health care costs and clinical and patients consequences in 
Generalized Anxiety Disorder (GAD) subjects with partial response (PR) to previous 
SSRI course in medical practice in Spain. Methods: Post-hoc analysis of patients 
with PR to SSRI monotherapy enrolled in a prospective 6-month naturalistic study. 
PR was defined as a Clinical-Global-Impression scale score > 3 and insufficient 
response with persistence of anxiety symptoms > 16 in the Hamilton-Anxiety scale. 
Two groups (based on psychiatrist judgment) were analyzed 1) adjunctive therapy 
(AT) with pregabalin (150-600 mg/day) to existing therapy; or 2) usual care (switching 
to a different SSRI or adding another anxiolytic different than pregabalin). Costs 
estimation used year-2009 prices for GAD related health care resources utilization. 
Consequences were a health profile based on the combination of psychiatrist-based-
measurements [HAM-A, CGI and Montgomery-Asberg-Depression-Rating (MADRS) 
scales], and patient-reported-outcomes [sleep (MOS-sleep), disability (WHO-DAAS 
II) and quality-of-life/quality-adjusted-life-year gain (EQ-5D)]. Changes in both 
health care costs and scale scores were compared separately at end-of-trial visit 
by a general-linear-model with covariates. Results: Four-hundred-eighty-six 
newly prescribed pregabalin and 239 UC GAD patients [mean (SD) HAM-A 26.7 (6.9) 
and CGI 4.1 (0.5)] were analyzed. Adding pregabalin was associated with signifi-
cantly higher mean (95% CI) score reductions vs. UC in HAM-A [-14.9(-15.6;-14.2) vs. 
-11.2(-12.2;-10.2), p< 0.001] and MADRS [-11.6(-12.2;-10.9) vs. -7.8(-8.7;-6.8), p< 0.001]. 
Changes in all patient-reported-outcomes favored significantly patients receiving 
pregabalin, including QALY gain; 0.13(0.12;0.14) vs. 0.09(0.07;0.10), p< 0.001. Health 
care costs were significantly reduced in both cohorts yielding similar 6-month costs; 
€ 1543 (1375;1711) UC and € 1497 (1380;1614) pregabalin, p= 0.661. The effect of sex on 
costs and consequences were negligible. ConClusions: In medical practice, GAD 
patients with PR to SSRI experienced greater consequences improvements with 
adjunctive therapy with pregabalin versus UC, without increasing health care cost. 
The effect of pregabalin was independent of patient gender.
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treatMent based on dIscrete event sIMulatIon ModelIng (desM): 
agoMelatIne versus MatrIx coMParator of escItaloPraM, sertralIne 
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objeCtives: To compare cost-effectiveness of agomelatine versus an escitalo-
pram-sertraline-venlafaxine matrix comparator. Methods: A DESM describes 
course of depressive disorders with acute , continuation, and maintenance treat-
ment of depression in Thai setting for 24 months. A sample of 250,000 patients 
with 100 simulations were assumed with Exigo® model. Antidepressants were 
analyzed for treatment of episodes(12-24 weeks),continuation phase(6-9 months), 
maintenance phase over 2 years follow-up. Data inputs included Thai data on 
disease parameters; Cost included antidepressants, drugs for insomnia, sexual 
side-effects, cognitive behavioral therapy(CBT), electroconvulsive therapy(ECT) 
and mean cost of psychiatric visits. Impact measures were derived from a sys-
temic review. Results were presented as cost(Thai-Baht currency-THB) per Life-
Year-Remission(LYR) averted and Quality-Adjusted Life Year(QALY) compared with 
branded antidepressants in the matrix comparator (46%escitalopram, 33%ser-
traline, 21%venlafaxine). Model simulation initiated with either agomelatine 
25mg or comparators(escitalopram10mg,sertraline100mg,venlafaxine 150mg 
by random selection). Relapse cases required dose increase fro each antidepres-
sant, addition of CBT and ECT. Data on impact of treatment on quality of life in 
patients free from relapse, sexual side effects, insomnia were taken from cochrane 
database. Results: During 24 months, patients treated with agomelatine cost 
15,814.2THB and 20,232.0THB per LYR and QALY gains, whereas with compara-
tor cost 17,999.6THB and 23,431.7THB per LYR and QALY gains. As a result, the 
incremental cost-effectiveness ratio(ICER) shows that agomelatine is the most 
cost-effective antidepressant for episodic treatment with/without continua-
tion or maintenance phase, its cost being lower than comparator by 153,283 and 
83,645 THB per LYR and QALY. These results were robust, probability sensitiv-
ity analysis suggested that agomelatine was effective for a willingness-to-pay 
of 300,000THB,95%CI of -146,120.4 to -179,651.0THB per QALY, with probability of 
> 0.90. ConClusions: Based on the model, agomelatine is the most cost-effective 
